United States : Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma

Press/Media

Period13 Dec 2022

Media coverage

1

Media coverage

  • TitleUnited States : Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma
    Media name/outletTendersInfo – News
    Country/TerritoryIndia
    Date13/12/22
    PersonsAjai Chari